Arcturus Therapeutics is trading at $11.48, up 10.22%, with the move appearing to track a broader biotech rally.
- No clear Arcturus-specific announcement was found to explain the October 20 move.
- Biotech ETF XBI is up 2.1%, amid positive sentiment following Merck KGaA’s agreement to acquire Silence Therapeutics and reported positive clinical-trial news. Reuters confirmed the acquisition announcement.
- Trading-volume details were unavailable.